The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
Mesothelioma
HMPL-453 in Advanced Malignant Mesothelioma
This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 in patient with advanced Malignant Mesothelioma
2019 Mesothelioma Treatments in Review
There have been many different advances in medicine benefitting mesothelioma patients, and over the course of 2019, different clinical trials have shown that there is still hope for them. One of the clinical trials in 2019 studied Nivolumab, also called Opdivo, as a first- and second-line treatment for mesothelioma. The[…]
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
Different Mesothelioma and Cancer Support Groups
Many times, when people are diagnosed with mesothelioma, they don’t know where to turn. Such a devastating illness can be very isolating and can even cause depression. It might be hard to handle a mesothelioma diagnosis, but people can have hope and support from around the country and even the[…]
Oncolytic Viruses with Standard Chemotherapy can Help Mesothelioma Patients
Mesothelioma is a cancer with a poor prognosis. People who are diagnosed do not normally have many options, but can at least have hope because of different clinical trials. Clinical trials can help find new treatments and medications to better help mesothelioma sufferers. A clinical trial in Oslo, Norway is[…]
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors.
Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Shorter Survival for Mesothelioma Patients Linked to Specific Biomarker
Mesothelioma is a very aggressive cancer with a poor prognosis. When diagnosed, patients can sometimes be given just a few months to live. Doctors and researchers are continuing to find treatment options to help cure, extend, or at least make patients’ lives better. Some researchers are looking at biomarkers, which[…]
Upcoming Mesothelioma Events in 2020
If you are interested in learning more about mesothelioma, we have a curated list of different events coming up in 2020. If you live near or are able to travel to these events, they can help you and your loved ones understand the disease better. Mayo Clinic Radiation Oncology: Current[…]
Skip to content